IT201700025190A1 - Metodo in vitro e kit per predire l’andamento clinico e la sensibilita’ ai farmaci nei pazienti con nefropatia membranosa - Google Patents

Metodo in vitro e kit per predire l’andamento clinico e la sensibilita’ ai farmaci nei pazienti con nefropatia membranosa

Info

Publication number
IT201700025190A1
IT201700025190A1 IT102017000025190A IT201700025190A IT201700025190A1 IT 201700025190 A1 IT201700025190 A1 IT 201700025190A1 IT 102017000025190 A IT102017000025190 A IT 102017000025190A IT 201700025190 A IT201700025190 A IT 201700025190A IT 201700025190 A1 IT201700025190 A1 IT 201700025190A1
Authority
IT
Italy
Prior art keywords
membraneo
preducing
nephropathy
medications
kit
Prior art date
Application number
IT102017000025190A
Other languages
English (en)
Inventor
Gian Marco Ghiggeri
Luca Ghiggeri
Original Assignee
Pad 4 Di Emanuele Ghiggeri S A S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pad 4 Di Emanuele Ghiggeri S A S filed Critical Pad 4 Di Emanuele Ghiggeri S A S
Priority to IT102017000025190A priority Critical patent/IT201700025190A1/it
Priority to EP18159989.5A priority patent/EP3373008A1/en
Publication of IT201700025190A1 publication Critical patent/IT201700025190A1/it

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90283—Oxidoreductases (1.) acting on superoxide radicals as acceptor (1.15)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Rehabilitation Therapy (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IT102017000025190A 2017-03-07 2017-03-07 Metodo in vitro e kit per predire l’andamento clinico e la sensibilita’ ai farmaci nei pazienti con nefropatia membranosa IT201700025190A1 (it)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IT102017000025190A IT201700025190A1 (it) 2017-03-07 2017-03-07 Metodo in vitro e kit per predire l’andamento clinico e la sensibilita’ ai farmaci nei pazienti con nefropatia membranosa
EP18159989.5A EP3373008A1 (en) 2017-03-07 2018-03-05 In vitro method and kit for predicting clinical outcome in patients with membranous nephropathy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102017000025190A IT201700025190A1 (it) 2017-03-07 2017-03-07 Metodo in vitro e kit per predire l’andamento clinico e la sensibilita’ ai farmaci nei pazienti con nefropatia membranosa

Publications (1)

Publication Number Publication Date
IT201700025190A1 true IT201700025190A1 (it) 2018-09-07

Family

ID=59337790

Family Applications (1)

Application Number Title Priority Date Filing Date
IT102017000025190A IT201700025190A1 (it) 2017-03-07 2017-03-07 Metodo in vitro e kit per predire l’andamento clinico e la sensibilita’ ai farmaci nei pazienti con nefropatia membranosa

Country Status (2)

Country Link
EP (1) EP3373008A1 (it)
IT (1) IT201700025190A1 (it)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113899908B (zh) * 2021-09-22 2024-05-28 深圳临研医学有限公司 磷酸化蛋白质在膜性肾病中的应用
EP4501965A1 (en) * 2022-03-29 2025-02-05 Chengdu Di'ao Pharmaceutical Group Co., Ltd. Antibody, fusion protein and use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017009245A1 (en) * 2015-07-10 2017-01-19 Chu De Nice Prognosis and monitoring of membranous nephropathy based on the analysis of pla2r1 epitope profile and spreading

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2977758A1 (en) * 2014-07-24 2016-01-27 Université De Nice Sophia Antipolis Methods and kits for monitoring membranous nephropathy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017009245A1 (en) * 2015-07-10 2017-01-19 Chu De Nice Prognosis and monitoring of membranous nephropathy based on the analysis of pla2r1 epitope profile and spreading

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BRUSCHI MAURIZIO ET AL: "Glomerular Autoimmune Multicomponents of Human Lupus Nephritis In Vivo (2): Planted Antigens", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, WILLIAMS AND WILKINS, BALTIMORE, MD, US, vol. 26, no. 8, 1 August 2015 (2015-08-01), pages 1905 - 1924, XP009500345, ISSN: 1046-6673, DOI: 10.1681/ASN.2014050493 *
C. MURTAS ET AL: "Coexistence of Different Circulating Anti-Podocyte Antibodies in Membranous Nephropathy", CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 7, no. 9, 5 July 2012 (2012-07-05), pages 1394 - 1400, XP055409223, ISSN: 1555-9041, DOI: 10.2215/CJN.02170312 *
MAURIZIO BRUSCHI ET AL: "Direct characterization of target podocyte antigens and auto-antibodies in human membranous glomerulonephritis: Alfa-enolase and borderline antigens", JOURNAL OF PROTEOMICS, ELSEVIER, AMSTERDAM, NL, vol. 74, no. 10, 10 May 2011 (2011-05-10), pages 2008 - 2017, XP028272518, ISSN: 1874-3919, [retrieved on 20110519], DOI: 10.1016/J.JPROT.2011.05.021 *

Also Published As

Publication number Publication date
EP3373008A1 (en) 2018-09-12

Similar Documents

Publication Publication Date Title
IL256673B (en) Vascularized in vitro perfusion devices, methods of fabricating, and applications thereof
PL3303632T3 (pl) Terapeutyczne i diagnostyczne sposoby stosowane w nowotworze
HUE043785T2 (hu) Módszerek és anyagok humán pluripotens õssejtek hematoendothelialis differenciálására meghatározott körülmények között
CL2015003395A1 (es) Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad
CL2014002358A1 (es) Formas polimorficas de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluoro-3-fenilquinazolin-4(3h)-ona; metodos de preparacion; composiciones farmaceuticas que las comprenden y uso en el tratamiento del cancer.
IL239923A0 (en) Solid solution compositions and use in cardiovascular disease
HUE050156T2 (hu) Anti-CD3 antitestek és alkalmazási eljárások
SI2986304T1 (sl) Farmacevtski sestavek, postopki za zdravljenje in njegove uporabe
HUE051982T2 (hu) Anti-alfa-szinuklein antitestek és alkalmazási eljárások
EP3362060A4 (en) BIOMARKERS FOR DIABETES AND TREATMENT OF DIABETES-BASED ILLNESSES
DK3020408T3 (da) Traditionel kinesisk medicinsammensætning og fremstilling og anvendelse heraf
DK2964088T3 (da) Vaginalt lægemiddeladministrations- og/eller diagnosesystem
SI3319612T1 (sl) Oksisteroli in postopki za uporabo le-teh
EP2968298A4 (en) Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
PL3004112T3 (pl) Pochodne pirazolo-pirolidyn-4-onu oraz ich zastosowanie w leczeniu choroby
HUE037673T2 (hu) Szulfonil-piperidin-származékok és alkalmazásuk prokineticin-mediált betegségek kezelésére
IL245936A0 (en) Methods of treating hematological cancers and predicting clinical sensitivity to leanlidomide using biomarkers
DK3057979T3 (da) Proteiner med diagnostiske og terapeutiske anvendelser
LT2958624T (lt) Transplantuotų pacientų transplantanto prieš šeiminiką ligos gydymas
DK3049473T3 (da) Dobbeltderivatiserede chitosannanopartikler og fremgangsmåder til fremstilling og anvendelse heraf til genoverførsel in vivo
PT2905335T (pt) Anticorpo anti-hdlk-1 tendo uma atividade anti-tumoral in vivo
EP2988731A4 (en) COMPOSITION TO REDUCE CRUSTING AND TO PROMOTE WOUND HEALING
ME02993B (me) Laktoferin za upotrebu u dijagnozi ili prognozi alchajmerove bolesтi
HRP20181352T1 (hr) Postupci i reagensi za održavanje vijabilnosti stanica raka u kirurški odstranjenom tkivu
IT201700025190A1 (it) Metodo in vitro e kit per predire l’andamento clinico e la sensibilita’ ai farmaci nei pazienti con nefropatia membranosa